Here’s what most articles aren’t telling you: BA.3.2 “Cicada” gets all the headlines, but it’s not even the dominant variant right now. As of May 2026, XFG.1.1 — a descendant of the “Stratus” recombinant strain — accounts for 32% of U.S. COVID cases, per CDC surveillance data cited by Nebraska Medicine’s Dr. Mark Rupp. If you’re trying to understand your actual risk today, that context matters.
So let’s cut through the noise and look at what’s actually circulating, what it means for your health, and what you should do about it.
What’s Actually Circulating Right Now
XFG.1.1 is the variant you’re most likely to encounter in the U.S. right now. It’s a recombinant strain — essentially a genetic mashup of LF.7 and LP.8.1.2. and it descended from XFG “Stratus,” which briefly dominated at roughly 79% of U.S. cases back in September 2025. XFG at 13% and XFG.14.1 at 8% round out the top three. These variants are spreading, but they haven’t triggered a dramatic surge.
BA.3.2, nicknamed “Cicada” in media coverage (not an official WHO designation, the WHO only uses “BA.3.2”), is the variant researchers are watching closely. First detected in South Africa in November 2024 and spotted in the U.S. at San Francisco International Airport on June 27, 2025, it’s now been found in 33 countries and more than half of U.S. states. German researchers published findings in The Lancet showing BA.3.2 outcompetes six other variants at evading antibodies from the current LP.8.1-adapted mRNA vaccines.
That’s a notable finding. But here’s the thing. despite reaching 30% of sequences in Denmark, Germany, and the Netherlands in late 2025, it didn’t produce substantially higher COVID hospitalizations there. Lab data and real-world risk aren’t always the same story.
Do Current Vaccines Still Help?
Yes, but with an asterisk. The 2025–26 Pfizer/BioNTech and Moderna vaccines both target the LP.8.1 antigen, and BA.3.2 carries 70–75 spike protein mutations relative to that antigen. That’s a meaningful gap. Reduced effectiveness at preventing mild infection is a real concern.
But the vaccines still protect against severe disease and hospitalization. That’s the bit that counts most. If you’re 65 or older, immunocompromised, or otherwise high-risk, Paxlovid remains effective against circulating variants per current expert guidance. take it early if you test positive.
One thing I find genuinely underreported: the CDC quietly shifted its vaccine guidance in 2025, now primarily recommending COVID shots for adults 65 and older and high-risk individuals, with “shared clinical decision-making” for everyone else. That’s a significant policy change. Some infectious disease specialists worry this will erode population immunity exactly when immune-evading variants like BA.3.2 are emerging. It’s a reasonable concern worth discussing with your doctor.
How to Know If You’re Infected (And What to Do)
Your at-home rapid test can’t tell you which variant you have. Genomic sequencing is required for that, and it’s not publicly accessible. What your rapid test can do is confirm active COVID infection, iHealth Labs at-home antigen tests have been shown to detect XFG and other current variants, so use one when symptoms appear.
And yes. symptoms across XFG.1.1, BA.3.2, flu, and RSV are nearly identical. Sore throat, fatigue, congestion. The “razor blade throat” some people describe online is not unique to 2026 variants; a severe sore throat has been documented with COVID since 2020.
What I’d Actually Do
I’d stop fixating on variant names and focus on a simple checklist. Are you 65 or older, or immunocompromised? Get your 2025–26 updated shot if you haven’t. Test early when symptoms hit. If you test positive and you’re high-risk, call your doctor about Paxlovid within the first two days.
The WHO’s TAG-CO-VAC flagged BA.3.2 for potential inclusion in the fall 2026 booster formulation. That decision is still pending. Worth keeping an eye on, especially if you’re eligible for that updated shot.
Stay informed. Don’t panic. But don’t dismiss these variants either. The risk is real for vulnerable groups, and hybrid immunity only stretches so far.
Photo by Towfiqu barbhuiya on Pexels
